The €500 million (~$586 million) funding target would be one of the largest pre-launch raises in AI history, reflecting investor confidence in LeCun’s vision of moving beyond today’s large language models.
“Silicon Valley is completely hypnotized by the current models of generative AI,” LeCun explained earlier this month at the AI-Pulse conference. “To pursue this kind of new research, you have to go outside the Valley—to Paris.”
The partnership with Nabla provides immediate applications for AMI’s technology. The health-tech company will gain first access to world model technologies, enabling it to develop FDA-certifiable AI systems for healthcare. LeBrun’s transition from Nabla CEO to AMI Labs CEO signals deep integration between the two companies, though he will remain chairman and chief AI scientist at Nabla.
